KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.

Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, Myung-Ju Ahn, Wan Qin Chong, Anna Spreafico, Sung-Bae Kim, Gwo Fuang Ho, Priscilla B Caguioa, Nuttapong Ngamphaiboon, Ramona F Swaby, Bo Wei, Andrea L Webber, John Kang, Burak Gumuscu, Jianda Yuan, Lillian L Siu

Cancer Med 15(2) e71496

PMID41631899
PMCIDPMC12866814
DOI10.1002/cam4.71496
发表日期2026-02-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:ROC 图;FIGURE 2:ROC 图;FIGURE 3:非 KM 图;FIGURE 4:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Plasma Epstein-Barr virus (EBV) DNA has clinical utility for prognosis, recurrence, surveillance, and treatment response in nasopharyngeal carcinoma (NPC). This exploratory analysis evaluated associations between plasma EBV DNA load and clinical outcomes in participants treated with pembrolizumab or chemotherapy in the phase 3 KEYNOTE-122 trial (NCT02611960). METHODS: Participants with platinum-pretreated, histologically confirmed, EBV-positive, recurrent/metastatic NPC were randomly assigned (1:1) to pembrolizumab 200 mg intravenously every 3 weeks (≤ 35 cycles) or standard of care (SOC; investigator's choice of capecitabine, gemcitabine, or docetaxel). Associations between baseline plasma EBV DNA load as a continuous variable and plasma EBV DNA fold change at cycle 2 day 1 (C2D1), with clinical outcomes (progression-free survival [PFS], overall survival [OS], and objective response rate [ORR]) were evaluated within each treatment arm. Nominal significance was prespecified at 0.05 for 1-sided p values. RESULTS: Of 228 treated participants, 215 (94.3%) had evaluable baseline plasma EBV DNA load data (pembrolizumab, 111; SOC, 104). Baseline plasma EBV DNA load was negatively associated with PFS and OS for pembrolizumab and SOC (both p < 0.005) but not ORR (p = 0.105, pembrolizumab; p = 0.473, SOC). Larger decreases in plasma EBV DNA load at C2D1 relative to baseline were associated with improved PFS, OS, and ORR for pembrolizumab and SOC (p ≤ 0.005). CONCLUSIONS: Higher baseline plasma EBV DNA load was negatively associated with outcomes in participants with NPC treated with pembrolizumab or SOC. These findings provide additional support for plasma EBV DNA as a prognostic biomarker for NPC. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02611960.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1(A) Receiver operating characteristic curves of baseline plasma EBV DNA a in predicting clinical outcome to pembrolizumab and SOC and (B) association between continuous baseline plasma EBV DNA load and ORR. AUC, area under the curve; AUROC, area under the receiver operating characteristic curve; EBV, Epstein–Barr virus; ORR, objective response rate; SOC, standard of care. a In log 2 scale. *AUROC calculated in the direction based on the hypothesized direction of effect.
非 KM Figure
FIGURE 2Receiver operating characteristic curves of fold change of plasma EBV DNA a from baseline at C2D1 in predicting clinical outcomes for treatment with pembrolizumab and SOC. AUC, area under the curve; AUROC, area under the receiver operating curve; C2D1, cycle 2 day 1; EBV, Epstein–Barr virus; SOC, standard of care. a In log 2 scale. *AUROC calculated in the direction based on the hypothesized direction of effect.
非 KM Figure
FIGURE 3Correlation between baseline plasma EBV DNA load and tumor size measurement in both arms prior to treatment. EBV, Epstein–Barr virus.
非 KM Figure
FIGURE 4(A) PFS and (B) OS by baseline plasma EBV DNA load subgroup and (C) PFS and (D) OS by plasma EBV DNA load fold change in each treatment arm. EBV, Epstein–Barr virus; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; SOC, standard of care. Median, 15.8 log 2 copies/mL; median, −0.7649 log 2 copies/mL.
非 KM Figure